VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

• Status: Terminated
• Trial end date: 2019-01-14
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vical
• Treatments: Amphotericin B; Isavuconazole; Liposomal amphotericin B; VL-2397; Voriconazole

Criteria

Inclusion Criteria:

• Acute Leukemia (AML or ALL) patient or allo-HCT recipient with a diagnosis of IA

Exclusion Criteria:

• Pregnant or breastfeeding

• IA involving sites other than lungs and sinuses

• Graft failure, acute or extensive chronic GvHD

• Uncontrolled diabetes